课件：生命科学基础综合自身免疫病.ppt

Highly purified population of FoxP3+ Treg cells for adoptive cell therapy. Peripheral blood mononuclear cells will be isolated from the peripheral blood of a patient, and stimulated in vitro with anti-CD3 and anti-CD28 mABs in the presence of IL-1β, IL-6, IL-2, IL-15, IL-21 and IL-23 for 7 days. This step is necessary to increase the limited number of circulating FoxP3+ TRegs, and to induce differentiation of a fraction of FoxP3+ T cells with potential to become IL-17-producing cells. Next, CD4+ T cells will be isolated by negative selection using an immunomagnetic beads technique. Subsequently, CD4+ T cells will be stained for bead-conjugated anti-CD49d and anti-CD127. In this step, the cells double positive for CD49d and CD127 (which are the IL-17-producing cells) will be removed, and highly purified FoxP3+ TRegs will thus be isolated by negative selection (being double negative for CD49d and CD127). Finally, this fraction of functional TReg cells, which are not positively but negatively selected by antibodies, can be infused into the patient. * Antigen-specific tolerogenic therapies are appealing from a safety point of view because they are not expected to induce global immunosuppression like systemic approaches. Conversely, it is still not clear whether induction of tolerance to a small number of dominant selfantigens will efficiently control autoimmunity after epitope spreading has occurred. Analogues 口服耐受：High-dose oral treatment results in the induction of T-cell anergy or the deletion of peripheral antigen-specific T cells. Low doses of oral antigen act by bystander suppression or by inducing regulatory-celld riven tolerance within the target organ. Although the use of oral tolerance remains an attractive possibility for preventing the onset of autoimmune disease, this therapy is currently limited in its ability to induce tolerance in ongoing disease, potentially limiting its usefulness for treating human autoimmune disease. Peptide Advantages: lack pote